Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Trial Profile

Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ANCHOR
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 13 Jun 2017 Results of ANCHOR study subanalysis presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 12 Jun 2017 According to an Amarin Corporation media release, a post-hoc analysis in the subgroup of statin-treated women with persistent high triglycerides and diabetes mellitus type 2 from this trial will be presented at American Diabetes Association 77th Scientific Sessions.
    • 16 Nov 2016 Results of post hoc subgroup analysis (in women, n=179) presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top